NASDAQ: IMDXInsight Molecular Diagnostics Inc Stock
$5.43-0.33 (-5.73%)
Updated Jun 11, 2026
IMDX Price
$5.43
Fair Value Price
N/A
Market Cap
$175.34M
52 Week Low
$2.33
52 Week High
$8.51
P/E
-3.62x
P/B
-16.4x
P/S
58.09x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.95M
Earnings
-$47.84M
Gross Margin
51.3%
Operating Margin
-2,449.36%
Profit Margin
-2,454.6%
Debt to Equity
-4.78
Operating Cash Flow
-$24M
Beta
1.07
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IMDX Overview
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IMDX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
C
IMDX
Ranked#33 of 44
Ranked#33 of 44
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.66 | A | |
| $129.55 | B | |
| $16.39 | B |
Be the first to know about important IMDX news, forecast changes, insider trades & much more!
IMDX News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IMDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMDX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IMDX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
IMDX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more IMDX due diligence checks available for Premium users.
Valuation
IMDX fair value
Fair Value of IMDX stock based on Discounted Cash Flow (DCF)
Price
$5.43
Fair Value
-$6.14
Undervalued by
188.44%
IMDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IMDX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.62x
Industry
16.18x
Market
13.95x
IMDX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-16.4x
Industry
3.54x
IMDX's financial health
Profit margin
Revenue
$32.0k
Net Income
-$4.3M
Profit Margin
-13,406.2%
IMDX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
IMDX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$40.4M
Liabilities
$51.1M
Debt to equity
-4.78
IMDX's short-term assets ($30.52M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMDX's long-term liabilities ($39.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMDX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IMDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.6M
Investing
-$613.0k
Financing
$24.7M
IMDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IMDX vs Diagnostic & Research Stocks
Insight Molecular Diagnostics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.